hot selling Bayer to trial improved plasticizer Germany

  • hot selling Bayer to trial improved plasticizer Germany
  • hot selling Bayer to trial improved plasticizer Germany
  • hot selling Bayer to trial improved plasticizer Germany
  • What is Bayer doing with its parenteral technology?
  • The company is now shifting its use to centre the development of parenteral treatments amongst other things. The new facility will use Bayer’s platform technology chemically and biologically based parenteral products.
  • What is Bayer VP SP 51022?
  • Home News Bayer Chemicals: A new plasticizer j ... Bayer Chemicals, has added a new polymeric plasticizer to its polymer additive range. The innovative trial product Ultramoll® VP SP 51022 was developed for the rubber-processing industry, for use in applications such as the manufacture of NBR-based printing rollers.
  • Why did Bayer invest in Berlin?
  • In the 23 November press release, Berlin’s governing mayor Kai Wegner said: “It is great to see a German company like Bayer driving innovation in Berlin. This investment not only demonstrates loyalty to the location but also strengthens our city as a renowned health metropolis.
  • Where is Bayer manufactured?
  • Bayer announced the launch of a manufacturing facility in Berlin, Germany, to meet future demands from the US, China and Europe. Logo of Bayer AG in Wuppertal, Germany – Bayer is a German multinational pharmaceutical and life science company. Credit: nitpicker via Shutterstock
  • Who is the new CEO of Bayer Crop Science?
  • Bayer's previous CEO,, Werner Baumann,, retired at the end of May after a 35-year career with the company. Bill Anderson, a native of Texas,, joined Bayer in April and assumed leadership of the company for the Crop Science division on June 1. Anderson was most recently the head of Roche’s pharmaceuticals division.
  • Is Bayer launching a new US cell therapy production plant?
  • As per a 10 October press release, the Berlin-headquartered company opened a new US cell therapy production plant to support the production of its Parkinson’s disease investigational cell therapy bemdaneprocel (BRT-DA01). The construction of the new facility was part of Bayer’s $500m to revamp its Berkeley biotechnology site.

Recommended hot-selling products